Inflammation in cancer leads to elevated IL-6 production by two mechanisms: Src-mediated activation of NF-κB leading to transactivation of the IL-6 gene, and rapid degradation of let-7 miRNA, which is a direct inhibitor of IL-6 expression [271]. The gene discussed is SRC; the disease is cancer.